Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2007

View Archived Issues

Targeting the hepatic phase of malaria infection proves effective in animal studies

Interim data from ragweed study of Tolamba

Antibacterial activity of Indonesian traditional remedy confirmed by Mayo Clinic researchers

New phase I trial investigates suicide gene therapy in pancreatic adenocarcinoma

Recent AstraZeneca patents describe novel therapeutic agents for thrombotic disorders

Recent AstraZeneca patent describes new treatment option for arrhythmia

Recent patents report novel contraceptives and therapeutic agents for sexual dysfunction

Orthovisc studied in osteoarthritis of the shoulder joint

Phase I/II study evaluates Neuprex in HSCT

MP-12 Rift Valley fever vaccine to be evaluated in phase II study

Seattle Genetics and Agensys to develop ADC therapies for cancer

Organon and AMC collaborate on novel therapy for rheumatoid arthritis

Epiphany completes license for KSHV

Fispemifene significantly increases testosterone in androgen-deficient men

Phase I study of VAS-203 cleared to begin in Germany

DelSite grants GelSite license to EndoBiologics for bacillary dysentery vaccine

Speedel studies new renin inhibitor SPP-1148 in phase I

Studies of Cleveland's Protectans 600 series reveal new stem cell discovery

Endoscopic ultrasound administration of TNFerade cleared for use in PACT trial

Voraxaze progress updated

International launch of Promus everolimus-eluting stent

Humanetics to begin phase I trials for BIO-300 for ARS

Forest completes acquisition of Cerexa

PBI-1402 studied in anemic patients with chronic kidney disease

Rotigotine transdermal patch reduces RLS symptoms in second phase III study

Swedish MPA approves Cipralex in OCD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...